Methodological matters on an Alzheimer&apos;s dementia trial: is a double-blind

randomized controlled study design sufficient to draw strong conclusions on

treatment? by Corrao, S. et al.
LETTER TO THE EDITOR
Methodological matters on an
Alzheimer’s dementia trial: is a
double-blind randomized controlled
study design sufficient to draw strong
conclusions on treatment?
Reply to Dr Mazza and colleagues
S. Corrao, R. Scaglione, L. Calvo and
G. Licata
Biomedical Department of Internal
Medicine, University of Palermo, Italy
Correspondence: Prof Salvatore Corrao,
Biomedical Department of Internal
Medicine, University of Palermo, Piazza
delle Cliniche 2, 90127 Palermo, Italy
(tel.: +39 091 6552065; fax: +39 091
6552165; e-mail: s.corrao@tiscali.it).
Keywords: alzheimers disease, dementia,
multi-infarct dementia, non-alzheimer
degenerative dementia
Received 2 September 2006
Accepted 23 November 2006
Sir,
We read with great interest the paper of
Mazza et al. [1]. The aim of the study is
noteworthy. Moreover, we appreciate the
overall study design that represents a
standard methodological approach for
reaching strong conclusions on treat-
ments. However, double-blind random-
ized controlled trials may have biases,
confounding factors or other
methodological errors. Wrong study
conclusions by misleading use of statistics
and other methodological matters [2] are
always possible and could incorrectly
inﬂuence clinician opinion and conse-
quently spoil health-care quality. There-
fore, we think a critical revision of the
work of Mazza et al. could be useful to
your readers to understand some import-
ant limitations in the study conclusions.
First of all, the trial studied a small
population sample and no eﬀort to
calculate sample size was made. Trials
with small population samples have scare
sensitivity and can bring to negative
results (no diﬀerences between groups).
In this case, no diﬀerences between
treatment groups (Ginkgo biloba versus
donepezil) could be justiﬁed by this
matter. Moreover, a drop-out at follow-up
‡20% compromises the overall quality of
a trial [3]. In this study, 60 patients out of
76 completed follow-up with a drop-out
of about 21%. On the other hand, some
considerations on the statistical analysis
section are needed. ANOVA only means
analysis of variance. A lot of diﬀerent
types of ANOVA exist. Therefore, the reader
should know what kind of ANOVA was
used. Moreover, outcomes were evaluated
by a psychometric test (the Syndrome
Kurtz test) and the Mini-Mental State
Examination. Diﬀerences in resulting
scores (obviously not normally
distributed) should be evaluated by
distribution-free (non-parametric)
statistical methods like, in this case, the
Kruskal–Wallis test (a non-parametric
ANOVA). However, multiple comparisons
between groups (when one has to manage
more than two groups) need a post hoc
evaluation test like (when applied to non-
parametric ANOVA) Dwass–Steel–Critch-
low–Fligner or Conover–Inman proce-
dures [4]. This study had three groups and
in no case pair-wise comparisons can be
made by a t-test (only used if the study
groups are exclusively two). For all these
reasons, no statements could be made on
the eﬃcacy of the two treatments. More-
over, this study cannot evaluate tolerabil-
ity of Ginkgo biloba due to the small
sample size and the short-time follow-up.
Having pointed out these aspects, this
study has scientiﬁc value, but readers
should be advised of all these considerable
limitations.
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